The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dzhambazov, B.
Right arrow Articles by Vestberg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dzhambazov, B.
Right arrow Articles by Vestberg, M.
The Journal of Immunology, 2006, 176: 1525-1533.
Copyright © 2006 by The American Association of Immunologists

Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules1

Balik Dzhambazov*, Kutty Selva Nandakumar*, Jan Kihlberg{dagger}, Lars Fugger{ddagger}, Rikard Holmdahl2,* and Mikael Vestberg*

* Medical Inflammation Research, Lund University, Lund, Sweden; {dagger} Department of Chemistry, Umeå University, Umeå, Sweden; and {ddagger} Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

In both collagen-induced arthritis (CIA) and rheumatoid arthritis, T cells recognize a galactosylated peptide from type II collagen (CII). In this study, we demonstrate that the CII259–273 peptide, galactosylated at lysine 264, in complex with Aq molecules prevented development of CIA in mice and ameliorated chronic relapsing disease. In contrast, nonglycosylated CII259–273/Aq complexes had no such effect. CIA dependent on other MHC class II molecules (Ar/Er) was also down-regulated, indicating a bystander vaccination effect. T cells could transfer the amelioration of CIA, showing that the protection is an active process. Thus, a complex between MHC class II molecules and a posttranslationally modified peptide offers a new possibility for treatment of chronically active autoimmune inflammation such as rheumatoid arthritis.




This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Rayment, T. W. Kooij, W. Zhang, C. Siebold, M. F. Murphy, D. Allen, N. Willcox, and D. J. Roberts
Evidence for the Specificity for Platelet HPA-1a Alloepitope and the Presenting HLA-DR52a of Diverse Antigen-Specific Helper T Cell Clones from Alloimmunized Mothers
J. Immunol., July 1, 2009; 183(1): 677 - 686.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Huan, L. J. Kaler, J. L. Mooney, S. Subramanian, C. Hopke, A. A. Vandenbark, E. F. Rosloniec, G. G. Burrows, and H. Offner
MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis
J. Immunol., January 15, 2008; 180(2): 1249 - 1257.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.